GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Newbury Pharmaceuticals NEWBRY.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

1.70

+5.59%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Newbury Pharmaceuticals

Its shares trade on Nasdaq Stockholm under the ticker NEWBRY.ST. It has been listed since 4 February 2022. In the fiscal year to 31 August 2026, it reported revenue of SEK 42.7m and a net loss of SEK 22.9m. At that date it held total assets of SEK 76.2m and shareholders' equity of SEK 19.6m.

Newbury Pharmaceuticals AB is a hybrid pharmaceutical company, which engages in specialty prescription drugs inn the Scandinavian markets. The company is headquartered in Lund, Skane. The company went IPO on 2022-02-04. The Company’s existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
4 Feb 2022

Leadership

Pay as last reported

  • Mr. Karl KarlssonExecutive Chairman of the Board
  • Mr. Lars MinorChief Executive Officer, since 2021
  • Mr. Christoffer TellChief Financial Officer
  • Mr. Fredrik HellqvistVice President of Sales and Marketing
  • Ms. Andrea KarnitschkySenior Director, Head of Business Development
  • Mr. Anil OkayBoard Member
  • Mr. Andreas HedskogIndependent Board Member
  • Mr. Johan StormqvistIndependent Director, since 2020

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Newbury Pharmaceuticals AB focuses on oncology, rare diseases, and neurology in Scandinavia.
  • The company's portfolio includes specialty prescription drugs for Scandinavian markets.
  • Newbury Pharmaceuticals AB has a strong presence in the Scandinavian pharmaceutical sector.

Weaknesses

  • The company's portfolio is limited to the Scandinavian market only.
  • Newbury Pharmaceuticals AB has no presence in other global markets.
  • The company's focus on specialty drugs may limit broader market reach.

Opportunities

  • Expanding into European markets beyond Scandinavia offers growth potential.
  • Newbury Pharmaceuticals AB can leverage its expertise in oncology and rare diseases.
  • The growing demand for specialty drugs in Europe presents new opportunities.

Threats

  • Competition from global pharmaceutical companies in Scandinavia is increasing.
  • Newbury Pharmaceuticals AB faces regulatory challenges in expanding internationally.
  • The company's reliance on the Scandinavian market increases vulnerability to regional economic shifts.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.